A new U.S. study found Anoro Elipta to be better than Bevespi Aerosphere or Stiolto Respimat at lowering the risk of disease ...

Please provide your email address to receive an email when new articles are posted on . Icenticaftor did not yield a dose response for trough FEV 1 at 12 weeks, but treatment was associated with ...

Although there isn’t currently a cure, you can find ways to live with chronic obstructive pulmonary disease (COPD)—thanks to bronchodilators, steroids, pulmonary rehabilitation, and supplemental ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...

Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that affects millions of people in the United States and around the world. Despite its prevalence, many individuals ...

Study authors shared late-breaking data in a session on clinical trial results in pulmonary medicine at the American Thoracic Society 2024 International Conference. Investigators shared late-breaking ...

COPD is a group of progressive lung diseases that includes emphysema and chronic bronchitis. Despite affecting an estimated 32 million people in the United States, as many as half are unaware they ...

In 2021, an estimated 14 million adults in the United States reported a diagnosis of chronic obstructive pulmonary disease (COPD), chronic bronchitis, or emphysema. If you’re not sure what the ...

Please provide your email address to receive an email when new articles are posted on . A cough score was used to determine severity and featured questions from three validated assessments. Poorer ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...